Verastem (NASDAQ:VSTM) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Wednesday.
VSTM has been the subject of a number of other research reports. HC Wainwright set a $15.00 price objective on Verastem and gave the company a “buy” rating in a research note on Thursday, November 8th. ValuEngine cut Verastem from a “buy” rating to a “hold” rating in a research note on Monday, December 17th. Zacks Investment Research cut Verastem from a “buy” rating to a “hold” rating in a research note on Saturday, January 5th. BTIG Research set a $17.00 price objective on Verastem and gave the company a “buy” rating in a research report on Tuesday, September 25th. Finally, Roth Capital set a $14.00 price objective on Verastem and gave the company a “buy” rating in a research report on Friday, November 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $14.78.
NASDAQ:VSTM traded down $0.08 during trading hours on Wednesday, reaching $3.97. 240,402 shares of the company traded hands, compared to its average volume of 2,655,306. The stock has a market capitalization of $301.81 million, a price-to-earnings ratio of -2.26 and a beta of 3.21. Verastem has a 1 year low of $2.77 and a 1 year high of $10.35. The company has a current ratio of 2.97, a quick ratio of 2.97 and a debt-to-equity ratio of 0.20.
Verastem (NASDAQ:VSTM) last announced its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.14. The company had revenue of $15.51 million for the quarter. As a group, equities research analysts predict that Verastem will post -1.4 EPS for the current year.
Institutional investors have recently bought and sold shares of the stock. HRT Financial LLC purchased a new stake in Verastem during the third quarter valued at $109,000. Pacer Advisors Inc. bought a new stake in Verastem during the third quarter valued at about $123,000. B. Riley Wealth Management Inc. bought a new stake in Verastem during the third quarter valued at about $127,000. Metropolitan Life Insurance Co. NY bought a new stake in Verastem during the second quarter valued at about $130,000. Finally, Voya Investment Management LLC bought a new stake in Verastem during the second quarter valued at about $139,000. Institutional investors own 48.83% of the company’s stock.
Verastem Company Profile
Verastem, Inc, operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Read More: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.